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Dynamin GTPase activity increases when it oligomer-
izes either into helices in the presence of lipid templates
or into rings in the presence of SH3 domain proteins.
Dynasore is a dynamin inhibitor of moderate potency
(IC50 ∼ 15μM in vitro). We show that dynasore binds
stoichiometrically to detergents used for in vitro drug
screening, drastically reducing its potency (IC50 = 479μM)
and research tool utility. We synthesized a focused set
of dihydroxyl and trihydroxyl dynasore analogs called
the Dyngo™ compounds, five of which had improved
potency, reduced detergent binding and reduced cyto-
toxicity, conferred by changes in the position and/or
number of hydroxyl substituents. The Dyngo compound
4a was the most potent compound, exhibiting a 37-fold
improvement in potency over dynasore for liposome-
stimulated helical dynamin activity. In contrast, while
dynasore about equally inhibited dynamin assembled
in its helical or ring states, 4a and 6a exhibited >36-
fold reduced activity against rings, suggesting that they
can discriminate between helical or ring oligomerization
states. 4a and 6a inhibited dynamin-dependent endocy-
tosis of transferrin in multiple cell types (IC50 of 5.7 and
5.8μM, respectively), at least sixfold more potently than
dynasore, but had no effect on dynamin-independent
endocytosis of cholera toxin. 4a also reduced synaptic
vesicle endocytosis and activity-dependent bulk endocy-
tosis in cultured neurons and synaptosomes. Overall, 4a
and 6a are improved and versatile helical dynamin and
endocytosis inhibitors in terms of potency, non-specific
binding and cytotoxicity. The data further suggest that
the ring oligomerization state of dynamin is not required
for clathrin-mediated endocytosis.
Key words: bulk endocytosis, drug discovery, dynamin,
high-throughput screening, small-molecule inhibitors,
synaptic vesicle endocytosis
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Dynamin is a large GTPase enzyme that sev-
ers membrane-bound clathrin-coated vesicles. Clathrin-
mediated endocytosis (CME) is involved in an array of
vital cellular processes, including the internalization of
activated receptors, sequestering growth factors, anti-
gen presentation, cytokinesis, synaptic transmission and
as an entry route for a variety of pathogens (1). There
is now a new field of dynamin pharmacology with the
development of multiple small-molecule inhibitors spe-
cific for the dynamin family of GTPases as powerful new
tools with which to study endocytosis. Small-molecule
dynamin inhibitors have attracted widespread attention
and have been used to study endocytosis, other aspects
of membrane dynamics and mitosis in a variety of cel-
lular systems (1–9). Small-molecule inhibitors offer many
distinct advantages over traditional means of dynamin inhi-
bition in cells by expression of dynamin GTPase mutants
or by small interfering RNA (siRNA)-mediated dynamin
knockdown which cannot be used to study rapid cellu-
lar effects. Small-molecule, cell-permeable inhibitors can
rapidly block endocytosis in minutes and their effects are
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typically reversible (3,10). Like all other research tools, they
are subject to their own limitations, such as potentially
poor cell permeability, cytotoxicity and risk of unknown
off-target actions. The field of targeted small-molecule
inhibitors of endocytosis has been recently expanded with
the development of the Pitstop™ compounds, which are
small-molecule clathrin inhibitors (11).
The first reported dynamin inhibitors were long-chain
ammonium salts called MiTMAB™ compounds (12),
followed by dimeric tyrphostins (13) and a series of
room temperature ionic liquids (RTILs) (14). Two of the
most potent inhibitors from the long-chain ammonium
salts, myristyl trimethyl ammonium bromide (MiTMAB)
and octadecyltrimethyl ammonium bromide (OcTMAB),
are potent and reversible inhibitors of endocytosis in
neuronal and non-neuronal cells, and selectively block
dynamin’s second function in cytokinesis (5,10,15,16).
Dynamin is also inhibited by psychotropic drugs such
as sertraline, a selective serotonin reuptake inhibitor
(17). There now exists a small but expanding ‘palette’
of compounds available to rapidly and reversibly block
dynamin by distinct mechanisms of action, thus operating
at different stages in its cycle of GTPase activity.
For example, MiTMAB, OcTMAB, RTILs and sertraline
block dynamin recruitment to membranes, while the
Dynole™ compounds and dynasore block dynamin after
its recruitment (4). Structure–activity relationship (SAR)
studies have afforded a range of inhibitors in the MiTMAB,
RTILs and Bis-tyrphostin (Bis-T) series (10,12–14,18,19).
The Dynole™ (4,20) the Iminodyn™ (21), Pthaladyn™ (22)
and Pyrimidyn™ (23) series all have extensive SAR. Dynole
34-2 (2-cyano-3-(1-(2-(dimethylamino)ethyl)-1H-indol-3-yl)-
N-octylacrylamide) is a 1.3±0.3μM dynamin inhibitor (4),
three of the Iminodyn series and a second-generation
Dynole compound 2-24 were the first nanomolar potent
dynamin inhibitors (20,21).
No SAR has yet been reported for the dynamin inhibitor
dynasore, which was discovered by a specific high-
throughput screen of a Chembridge library (DiversSet
E) of 16 320 small molecules against grb2-SH3 domain-
stimulated recombinant dynamin (3). Dynasore was
originally reported to inhibit three forms of dynamin
activity: (i) L-phosphatidylserine (PS) liposome-stimulated
dynamin, which induces dynamin to form a helix around
liposomes (note that we use the term ‘helix’ specifically
to indicate the nanospring structure of dynamin, involving
more than one turn of the ring); (ii) Grb2-stimulated
dynamin, the SH3 domains of which cross-link dynamin
tetramers into a potentially distinct conformational state
involving single rings (24,25); and (iii) self-assembly-
induced (SAI) activity, which is the basal activity stimulated
up to 10-fold by self-assembly of dynamin into single rings,
the formation of which is induced by high concentrations
of dynamin in low salt buffers (26). However, the relative
potency of dynasore in each of these systems was
not investigated. The mechanism of dynamin inhibition
by dynasore is not known, but the compound was
reported not to affect GTP binding, dynamin self-assembly,
oligomerization or lipid binding (3). It blocked clathrin-
mediated endocytic functions that are well known to
require dynamin, while it was without effect on clathrin-
and dynamin-independent endocytosis. Its ability to block
endocytosis in a wide variety of cellular systems has been
widely validated in the literature; however, it is not a
potent in-cell inhibitor.
Dynasore has undesirable non-specific and specific
binding properties in common with many other small-
molecule inhibitors. For example, it binds to serum
proteins, causing it to lose dynamin inhibitory activity
(27), limiting its use for many experimental designs.
We show here that dynasore also exhibits stoichiometric
binding to the trace level of detergents commonly used in
biological assays. Concerned by this potential limitation,
and with a background of previous development of
functionally active dynamin and endocytosis inhibitors, we
evaluated dynasore’s SAR. By focusing on the role of the
hydroxyl moieties (13,18,19), we developed a dynasore
analog family with greatly reduced or no non-specific
in vitro binding and improved potency. By employing
some elegantly simple medicinal chemistry strategies,
the Dyngo™ series of compounds was generated. This
includes a 37-fold more potent dynamin and endocytosis
inhibitor, Dyngo compound 4a, and a wholly detergent-
resistant inhibitor, 6a, both of which are more potent
than the parent in vitro and in a diverse range of cellular
endocytosis model systems. In preliminary reports, we
noted that 4a inhibits both dynamin I and II [IC50 for
sheep brain dynamin I of 380±0.05 nM (n=5) and for
recombinant rat dynamin II of 2.3±0.2μM (n= 3)], the
internalization of botulinum toxin in nerve terminals (7),
but not the clathrin-independent carrier (CLIC) pathway
(28). However, 4a and related dynasore analogs have not
been examined for CME or toxicity in non-neuronal cells
or for other modes of endocytosis. We now extensively
characterize the development of 4a and 6a, from the
Dyngo series of greatly improved dynasore analogs, as
more versatile cell biology tools with reduced cytotoxicity.
Results
Dynasore quantitatively binds detergents
We developed a one-step synthesis of dynasore (Figure
S1A, Supporting Information) (27) and tested its ability
to block the GTPase activity of dynamin I (purified from
sheep brain). Under our standard PS liposome-stimulated
dynamin I assay conditions, we found that dynasore was
effectively not an inhibitor of helical dynamin I GTPase
activity (Figure S1B) with an IC50 of 479μM (Figure S1C)
and had no effect on dynamin II (up to 1.5mM, not shown).
This was much higher than the previously estimated IC50
for dynasore of ∼15μM, although this value was obtained
using grb2-stimulated dynamin (3). To confirm that our
relatively high IC50 was not a specific property of our in-
house-synthesized dynasore, we verified this result using
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dynasore obtained commercially or from the original stock
from the Kirchhausen laboratory (Figure S1B). Helical
dynamin can also be stimulated with microtubules and
ring dynamin by grb2-SH3 domains or by self-assembly;
however, we found that dynasore did not block any of
these activities (Figure S1C). Dynasore has also been
previously found to be an inhibitor of CME (3), which
we confirmed using an automated quantitative assay of
transferrin-A594 (Tfn-A594) uptake in U2OS cells (Figure
S1D), observing an IC50 of 34.7μM. This verified the
efficacy of dynasore in cells in our hands.
We noted that no detergents were used in the original
dynasore study (3). Detergents are routinely used in
assays to reduce non-specific effects (29,30). Our
standard GTPase assay contained 0.06% Tween-80
(458μM) and 20 nM dynamin I, suggesting that this may
explain the discrepancy between our results and the
original report of dynasore’s efficacy (3). After redesigning
our assay to accommodate no detergent (noting that
such conditions greatly compromise the sensitivity and
dynamic range of the in vitro assay), the IC50 for dyna-
sore with PS-stimulated helical dynamin I dramatically
improved to 12.4±1.5μM (n=5, Table 1). We also noted
that increasing the dynamin concentration in the assay
to 40 nM, the IC50 similarly increased to 73.6±16μM,
indicating that IC50 values are dependent upon the
dynamin concentration in the assay (as expected) and
enzyme concentrations should be clearly noted in assay
descriptions. The inhibition of full-length helical dynamin
II (recombinant protein expressed in Sf21 cells) was also
restored when detergent was removed from the assay
(IC50 = 18.1± 0.2μM, n=2). These findings suggested
that dynasore binds to detergent with a stoichiometry
of 1:1, because 0.06% Tween-80 represents 458μM
detergent. This unfavorable property is reminiscent of a
report that dynasore binds to serum proteins and similarly
loses activity (27). Molecular modeling of dynasore bound
to Tween-80 suggested that the catechol moiety (i.e. the
dihydroxybenzaldehyde) may be the major contributor to
this interaction. As non-specific binding greatly decreases
the utility of any drug, we aimed to develop an improved
dynamin inhibitor, using dynasore as a lead compound,
by reducing detergent binding and improving potency.
Building a better dynasore
The structure of dynasore (Figure S1A) is chemically
similar to that of the Bis-T series of dynamin modulators
that we have previously reported (13). In that study, we
found that the position and number of the hydroxyls
around the phenyl ring contributed to their potency; thus,
we used this as a template to assist in the development of
a new series of compounds called the Dyngo compounds
(Table 1). Each Dyngo compound was synthesized via a
condensation reaction. Reaction of 3-hydroxy-2-naphthoic
acid hydrazide with a variety of mono-, di- and tri-
hydroxybenzaldehydes afforded a highly focused Dyngo
library 1 (1a–8a, Scheme S1).
Dynasore has two hydroxyls at C3′ and C4′ (on the phenyl
ring, a 3′,4′-catechol). When we initially screened the
focused library on the dynamin I GTPase helix assays, the
experiments were carried out in the presence of Tween-
80 (under which conditions dynasore returned an IC50 of
479±49μM). The results of this screen are summarized in
Table 1. While three analogs, 2a, 3a and 8a were inactive,
all other Dyngo compounds exhibited increased inhibition
compared to dynasore. In particular, the 2,3-dihydroxy (6a)
was about 90 times more potent than dynasore, with an
IC50 of 5.5μM, while the 2,4,5-trihydroxyl analog (4a) was
the most potent compound overall, with an IC50 of 2.7μM
(n=3), making it 177 times more active than dynasore.
When the SAR for library 1 was re-examined by GTPase
assay in the absence of Tween-80, markedly different
results were obtained (Table 1). Most, but not all, Dyngo
compounds exhibited up to 1000-fold enhanced dynamin
inhibition under the new assay conditions. Notably, the
greatest detergent sensitivity was observed with analogs
comprising at least one –OH moiety at either C3′ or C4′,
namely dynasore (C3′ and C4′), 5a (C3′ and C4′), 2a (C3
and C4), 3a (C3′ and C4′) and 8a (C3′). Thus, the number
and position of the –OH moieties clearly influenced not
only dynamin inhibition but also detergent sensitivity. The
compounds with the lowest detergent sensitivity (defined
as <10-fold potency change on removal of Tween) were
4a, 6a and 1a, each of which possessed a C2′-OH. Both
2a and 4a contain a C4′-OH moiety noted to be a major
contributor to Tween sensitivity. 2a lacks the free C5′-OH
and is 400-fold Tween sensitive, whereas 4a retains the
C5′-OH and is only sevenfold Tween sensitive. This sug-
gests that the removal of the C4′-OH or the inclusion of a
C5′-OH moiety would significantly reduce Tween sensitiv-
ity. 6a has a C2′-OH and no C4′-OH, and is the most
dynamin-active, detergent-insensitive analog (Table 1).
Further examination of the molecular basis of detergent
sensitivity led us to develop a second library of Dyngo com-
pounds (10a–14a, Table 1, Scheme S1, Library 2), which
confirmed the importance of –OH involvement in dynamin
inhibition and detergent binding. These are discussed in
detail in Supporting Information – Dyngo Library 2.
In summary, we highlight analogs 4a (Figure 1A) as the
most potent and 6a (Figure 1B) as being largely free of
detergent effects. In the absence of detergent, 4a exhib-
ited a 37-fold improved potency to 380 nM (Figure 1C),
making it only the third submicromolar dynamin inhibitor
yet reported, in addition to members of the Iminodyn
and Dynole-2 series (4,20). To optimally compare DynI
and II we prepared full-length recombinant versions of
both enzymes in Sf21 insect cells and compared their
IC50 values (Table 2). 4a was 2.1-fold selective for DynI
versus DynII inhibition in the absence of Tween, and
3.1-fold selective in its presence. 6a was the second
most potent inhibitor in our study and was equipotent
in the presence and absence (Figure 1D and Table 1) of
Tween-80, highlighting its total lack of detergent binding.
1274 Traffic 2013; 14: 1272–1289
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Table 1: Dyngo compound 4a inhibits dynamin I and CME
Name Structure
Formula
weight
DynI IC50
(μM) with
T-80
DynI IC50
(μM)
without T-80
CME IC50
(μM)
Library 1
Dynasore C18H14N2O4, 322.31 479±49 (n=3) 12.4± 1.5 (n=5) 34.7± 5.1 (n=9)
4a C18H14N2O5, 338.31 2.7±0.7 (n=3) 0.38±0.05 (n=5) 5.7±1.0 (n=7)
6a C18H14N2O4, 322.31 5.5±0.2 (n=3) 3.2±0.3 (n=3) 5.8±0.8 (n=5)
1a C18H14N2O4, 322.31 37.4 ±0.9 (n= 3) 4.4±1.0 (n=3) Not active (n= 3)
5a C18H14N2O5, 338.31 102 ±14 (n=2) 1.5±0.04 (n=2) 6.2± 2 (n=2)
2a C19H16N2O5, 352.34 Not active (n= 3) 3.3±1.0 (n=4) 9.6±0.4 (n=2)
3a C18H14N2O5, 338.31 Not active (n= 2) 1.5±0.3 (n=2) 9.8±1.5 (n=2)
8a C18H14N2O4, 322.31 Not active (n= 2) 47.0± 0.5 (n=2) 179± 20 (n=3)
Library 2
10a C20H17N3O3, 347.37 Not active (n= 3) 39.5± 4.5 (n=2) Not active (n= 2)
11a C21H17N3O2, 343.38 58.9 ±1.4 (n= 2) 44.2 ±19.4 (n=2) 63.4 ±4.4 (n= 2)
12a C20H14N4O2, 342.35 >100 (n=2) 24.6 ±4.1 (n= 2) Not active (n= 2)
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Table 1: Continued
Name Structure
Formula
weight
DynI IC50
(μM) with
T-80
DynI IC50
(μM)
without T-80
CME IC50
(μM)
13a C18H12N4O3, 332.31 30.6 ±5.0 (n= 6) 17.6± 3.5 (n=2) Not active (n=3)
14a C18H12N4O2S, 348.38 4.8 ±0.5 (n=4) 11.6± 1.6 (n=2) Not active (n=4)
A series of dynasore analogs (Dyngo compounds) were synthesized with substitutions in the (3,4-dihydroxybenzylidene)-hydrazide.
Illustrated is the structure of each compound, its chemical formula, formula weight and IC50 for inhibition of native sheep brain dynamin
I GTPase activity stimulated by PS liposomes, either in the presence or absence of Tween-80 (T-80) in GTPase assay. The last column
shows the CME IC50 for inhibition of Tfn-A594 uptake in U2OS cells after a 30-min preincubation with each compound. All compounds
were tested at multiple concentrations in 1% DMSO (in CME assay) and 3% (in GTPase assay) up to at least 1mM concentration.
Results are mean±SEM, for n=2–9 independent experiments.
Differential inhibition of dynamin oligomerized in the
helical or ring states
We next explored the capacity of the most potent analogs,
4a and 6a, to inhibit dynamin in different conformational
states. It is known that both PS and microtubules support
dynamin assembly into a helical shape (helical dynamin)
along a structural template (tubulated lipid or rigid micro-
tubules). PS uses the lipid-binding properties of dynamin
to assemble into a helix, while microtubules act as a
scaffold or template for dynamin helix assembly (31,32).
The helical oligomerization state of dynamin has been
associated with CME in cells and so the capacity of Dyngo
compounds to inhibit either helical or ring dynamin may
be of potential biological importance in a cellular context.
Dyngo series 4a inhibited PS-stimulated helical dynamin
and microtubule-stimulated dynamin with similar potency
(IC50 of 2.7 versus 3.3μM, respectively, in the presence
of Tween-80). This shows that 4a does not inhibit by
interferingwith dynamin’s lipid-binding properties, demon-
strating that it does not compete at the PH domain of
dynamin.
Without a template for helical assembly, dynamin’s
GTPase activity can be greatly stimulated by SAI activity
into single rings. However, the maximum activity of
self-assembled ring dynamin is 5- to 10-fold less than
that of helical dynamin; therefore, higher dynamin I
concentrations (50 nM) were required for increased assay
sensitivity. The SH3 domains of proteins such as grb2
stimulate dynamin SAI activity (24,25) as does dilution of
dynamin into low salt buffers at high concentrations (26).
In both situations, dynamin assembles as rings rather
than a helix (24–26,32). In the absence of Tween-80,
dynasore inhibited grb2-stimulated dynamin I with an IC50
of 38.2μM, which is only threefold less potent than PS-
stimulated inhibition (Table 3, noting that slightly different
dynamin I concentrations were used). This is consistent
with the original dynasore report (3). Strikingly, both 4a
and 6a were far less active against grb2-stimulated ring
dynamin (Figure 1E,F), with 4a being 100-fold less active
and 6a 36-fold less potent (Table 3). Dyngo compound 4a
did not disrupt the binding of dynamin I to the SH3 domain
of grb2 (Figure S2). Similarly, 4a did not affect dynamin
I binding to amphiphysin-SH3 or endophilin-SH3 domains
(Figure S2). At high protein concentrations dynamin self-
assembles and is activated, but SAI activity in the presence
of Tween (at 500 nM dynamin concentrations) was not at
all inhibited by 4a.
To explore the mechanism of 4a-mediated inhibition of
dynamin I GTPase activity, we conducted Michaelis–
Menten kinetic experiments with 4a and varying concen-
trations of GTP. Lineweaver–Burke plots demonstrated
that 4a is a non-competitive inhibitor of dynamin I (Figure
1G), consistent with previous observations made exam-
ining the kinetics on dynamin inhibition by dynasore (3).
To examine whether the Dyngo compounds might bind to
other key CMEproteins thatmight account for its inhibitory
actions, we performed in vitro assays to examine whether
dynasore or 4a and 6a inhibit clathrin or AP-2 protein
interactions with amphiphysin I, both of which are key
mediators of the early stages of CME. For the clathrin
assay, the binding of clathrin heavy chain to amphiphysin
1 was examined. None of the compounds inhibited this
interaction up to 300μM (Figure S3A). The AP-2 assay
examined the binding of the AP-2 alpha ear to amphiphysin
1. 6a and dynasore had no effect, whereas 4a had an
IC50 of 362μM, almost 1000 times less potent than
for dynamin I inhibition (Figure S3B). Therefore, these
compounds do not have off-target actions on these two
protein–protein interactions.
Overall, our findings demonstrate that the Dyngo com-
pounds do not target the GTPase-binding site within the
G domain, do not inhibit the binding of three different
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Figure 1: Dyngo compounds 4a and 6a are potent inhibitors of PS-stimulated dynamin helices. A and B) Compound structures.
C–F) Dose–response curves for inhibition of dynamin I GTPase activity by 4a and 6a. Helical dynamin I activity was stimulated by PS
liposomes in (C) and (D) or ring dynamin I was stimulated by grb2 in (E) and (F). All data were obtained in the absence of Tween-80.
IC50 values are shown in μM (see also Tables 1 and 2). G) Non-competitive kinetics of 4a with respect to GTP. The data depict 4a
concentration-dependent changes in a double-reciprocal plot between substrate (GTP at 50–250μM) and reaction velocity. The data
correspond to 4a concentrations at 6 ( ), 5 ( ), 2.5 ( ), 1 ( ) and 0.5 ( ) μM. Error bars represent the mean ± SEM of three independent
experiments each conducted in triplicate.
SH3 domains that bind different sites in dynamin’s PRD,
do not require the function of the PH domain and do not
have off-target actions on protein–protein interactions
involving amphiphysin I. Yet, we reveal that 4a and
6a inhibit helically assembled dynamin at least 36-fold
more potently than ring dynamin, in marked contrast to
dynasore, thus failing to inhibit the distinct conformational
state of ring dynamin.
4a inhibits cellular endocytosis
Prior to an extensive study of endocytosis in a variety
of cellular systems, we asked whether the lead Dyngo
Traffic 2013; 14: 1272–1289 1277
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Table 2: Relative IC50 values for inhibition of DynI and DynII by 4a
4a DynI (brain) DynI (rec) DynII (rec)
DynI
selectivity ratio
Absence of Tween 0.38±0.05 (5) 1.1±0.2 (8) 2.3± 0.2 (4) 2.1
Presence of Tween 4.9±0.9 (5) 30.0±8.2 (2) 92.3± 10.9 (5) 3.1
DynI [from brain or recombinant (rec) protein from Sf21 cells] was used at 20 nM and DynII (recombinant protein from Sf21 cells) at
50 nM in the GTPase assay. The selectivity ratio refers to the DynI (rec) IC50 divided by that of DynII (rec). Data are mean±SEM for the
number of independent experiments shown in brackets.
Table 3: Differential potency of dynamin inhibitors against grb2-
stimulated ring dynamin I
Compound
PS-stimulated
Dyn I,
IC50 (μM)
Grb2-stimulated
Dyn I,
IC50 (μM)
Dynasore 12.4±1.5 38.2±9.7
4a 0.38±0.05 39.2±1.6
6a 3.2±0.3 114±4.2
Data for grb2-stimulated dynamin GTPase activity was obtained
using 50 nM dynamin I (from brain). Data from PS-stimulated
dynamin (helix) used 20 nM (fromTable 1). Data are fromn=6 (6a)
or n=4 (all others) experiments, using complete IC50 curves that
were from independent experiments. All assays were conducted
without Tween-80.
compounds might be toxic to cells in culture (Figure S4).
Dyngo compounds 4a, 6a and dynasore did not exhibit
generalized cytotoxicity after 8-h exposure to HeLa cells
assayed by lactate dehydrogenase (LDH) activity (Figure
S4A,B). Prolonged exposure to Dyngo compounds (20 h)
did not affect cell membrane integrity, as determined by a
trypan blue exclusion assay (Figure S4C–F), nor did they
induce apoptotic cell death (analyzed by flow cytometry
in the quantitation of sub-G1 peak or by western blotting
for cleaved PARP, data not shown). These effects were
unchanged in the presence or absence of cell culture
serum. The small decrease in cell number after 20-
h exposure may suggest minor effects on cell growth
or division, consistent with what are known effects of
dynamin siRNA treatment (33) and its role in the final
stage of mitosis, cytokinesis (34). Longer cell exposure of
72 h to 4a and 6a did not have any effect on cell viability
or proliferation in a variety of cell lines using the standard
MTT assay; however, dynasore showed broad-spectrum
toxicity in all the cells under these conditions (Table S1).
Overall, 4a and 6a do not adversely affect cell viability and
were markedly improved over dynasore under conditions
of prolonged cell exposure for HeLa cells.
Dynasore was originally reported to inhibit the GTPase
activity of dynamin-like protein 1 (Dlp-1), which is
involved in mitochondrial fission. This raises the possibility
that dynasore and the Dyngo compounds may affect
mitochondrial morphology and/or dynamics in cells. We
investigated this by labeling mitochondria in live HeLa
cells using Mitotracker Green FM and imaging the cells
over time using confocal microscopy. These cells stably
expressed an mCherry-conjugated form of the nuclear
histone protein H2B, providing contrast to the green
mitochondria. Images from cells treated for 30 and 60min
with either 30μM 4a, 30μM 6a or 100μM dynasore are
shown in Figure S5. Dyngo series 4a and dynasore did not
mediate any changes in mitochondrial morphology (Figure
S4C,D). 6a appeared to causemitochondrial fragmentation
(Figure S5E). The lack of any 6a toxicity suggests that
this mitochondrial fragmentation had no effect on cell
viability. When cells were incubated in the presence of the
compounds for longer than 30min, all three compounds
caused a reduction in Mitotracker Green FM fluorescence
intensity, but the mechanism of which is unclear.
To determine whether the Dyngo compounds are
widespread cell-permeable and endocytosis inhibitors,
CME of fluorescent Tfn was compared in an automated
quantitative endocytosis assay in U2OS cells. The assay
consisted of over 1200 cells under serum-free conditions;
after preincubation with each analog for 30min the uptake
of fluorescent Tfn was measured. We refer to this endo-
cytosis as non-neuronal CME to distinguish it from CME
of synaptic vesicles in presynaptic terminals of neurons,
which is referred to as synaptic vesicle endocytosis (SVE).
In these cells, Tfn uptake is presumed to be mediated by
dynamin II, because this is the only isoform of dynamin
that they express, as determined by western blot (Figure
S6). In the CME assay, 4a, 6a and 5a were the most
potent, being six times more potent than dynasore under
the same conditions (Table 1). Dyngo compounds 2a and
4a were also active against non-neuronal CME, whereas
other analogs like 1a (Figure 2A and Table 1) had little or
no effect. There was no apparent correlation between in
vitro and in-cell activity, with potent dynamin-active com-
pounds like 1a and 14a having no effect on non-neuronal
CME (Table 1). This might be explained by low membrane
permeability of these analogs, their cellular metabolism or
rapid cellular efflux mechanisms. Dyngo compounds 4a
and 6a potently inhibited Tfn endocytosis with IC50 values
of 5.7±1.0μM and 5.8±0.8μM, respectively, approx-
imating the activity of the most potent small-molecule
endocytosis inhibitors previously reported [Dynole com-
pound 34-2 (4) and Iminodyn compound 22 (21)]. We
also investigated this further in NIH3T3 cells across a
range of 4a and dynasore concentrations, confirming that
these compounds selectively inhibit dynamin-dependent
endocytosis with much less effect on the uptake of
cholera toxin (CT; Figure S7). This is consistent with
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our previous preliminary electron microscopy report in
fibroblasts cells that 4a does not inhibit the uptake of CT
by CLICs, which is dynamin-independent (28).
We next examined the exposure time of U2OS cells to
the compound before an endocytic block was achieved,
using 4a or 6a at 10μM. Inhibition of non-neuronal CME
was observedwith as little as 5-min preincubation with 4a,
although 30min was required for complete abolition of Tfn
uptake (Figure 2B). The same trend was obtained with 6a
(Figure 2C). Therefore, 30-min preincubation was used for
most subsequent experiments. We then tested whether
the endocytic block with 4a and 6a was reversible. Cells
were incubated with 10μM of the compound for 30min,
before its removal and assay of non-neuronal CME by
Tfn uptake. This ‘wash out’ allowed us to determine
the length of time required for recovery of normal non-
neuronal CME. Ten minutes after the removal of 4a, we
observed a recovery to 70% of normal non-neuronal CME
levels (Figure 2D). Longer wash out times (up to 1 h)
resulted in over 80% recovery. In the same experiment
using 6a, we found that non-neuronal CME was restored
to 70% of the normal level after 60min of wash out
(Figure 2E). Hence, the actions of 4a and 6a are rapid and
reversible.
Dynasore is reported to lose non-neuronal CME inhibition
in cell culture after exposure to serum (27). Given that 4a
and 6a exhibited reduced detergent binding, we examined
whether serum binding was also reduced compared
to dynasore. All three compounds bound strongly to
human serum albumin (4a: 99.4% bound, 6a: 99.7%
and dynasore: 98.8% bound), suggesting that the in vitro
non-specific binding differences between them relate to
Tween-80 rather than to albumin. We next examined
whether 4a shows improved non-specific binding by
assaying non-neuronal CME in the presence of serum or
albumin protein. Dynasore lost virtually all CME inhibitory
activity when used in the presence of 10% FBS or 1%
BSA for 60min (Table 4), extending a previous report (27).
In contrast, 4a and 6a were still active in the presence
of 5 or 10% FBS or 1% BSA but were at least 20-
fold less potent (Table 4). Reducing the FBS to 1%
or the BSA to 0.1% increased the potency of all three
compounds; however, there was still about 10-fold less
endocytosis inhibition compared to the absence of serum
protein (Table 4). When taking their dynamin potency
into consideration, the effects of Dyngo compounds and
dynasore on endocytosis are reduced to similar extents by
serum or albumin. Therefore, although Dyngo compounds
remain more active than dynasore in the presence of
serum or albumin, this may simply be owing to their
improved potency.
Dyngo compounds inhibit synaptic vesicle
endocytosis
Much of the research on the involvement of dynamin
in endocytosis has focused on SVE. SVE has many
features in common with the non-neuronal CME pathway,
but is primarily mediated by dynamin I, whereas non-
neuronal CME of Tfn is mediated by dynamin II. We
examined whether 4a and 6a inhibited SVE (Figure 3).
A dose–response for inhibition of SVE was established
by examining uptake of the styryl dye FM4-64 in rat
brain synaptosomes using a 96-well microplate assay (35).
Dyngo compound 4a inhibited SVEwith an IC50 of 26.8μM
(Figure 3A, n=6) and 6a with an IC50 of 70.1μM (Figure
3B, n= 6). Dynasore was seven times less potent, with
an IC50 of 184μM under the same conditions (Figure 3C,
n=3). Inhibition of SVE by 4a was further investigated
in cultured cerebellar granule neurons (CGNs). SVE was
measured by the activity-dependent loading and unloading
of the styryl dye FM1-43 (Figure 3D, representative images
are shown in Figure S8A–D). After incubation with 30μM
4a for 15min, the loading of FM1-43 was inhibited,
suggesting a blockade in synaptic vesicle turnover, i.e.
the number of synaptic vesicles undergoing exocytosis
and then endocytosis (Figure 3E). This is consistent with
previous reports that dynasore does not affect synaptic
vesicle exocytosis but blocks SVE (2). To confirm that
the block of SV turnover by 4a was due to the arrest
of SVE, its effect on FM1-43 unloading (SV exocytosis)
was determined. Dyngo compound 4a did not have a
significant acute effect on SV exocytosis, indicating that
its predominant action was the specific inhibition of SVE
(Figure 3F).
Dyngo series 4a inhibition of SVE was investigated
in neurons in situ within brain slices by studying
depolarization-induced changes in membrane capacitance
at the Calyx of Held. Control recordings showed a
typical rapid increase in membrane capacitance at the
onset of stimulation, indicative of exocytosis of synaptic
vesicles, followed by a decline in capacitance associated
with SVE (Figure 3G,H, black traces). Dynasore (100μM,
5-min preincubation) has been previously shown to
inhibit SVE in this experimental system (36), and we
reproduced similar observations (Figure S9) using acute
and direct application of 800μM dynasore in a puffing
pipette. We next examined the effects of 4a at a lower
concentration (using direct application of 300μM in the
puffing pipette) than was used for dynasore. These
concentrations were selected to account for direct drug
application rather than via preincubation. The decaying
phase of the trace was abolished, suggesting that
4a caused a complete blockade of SVE (Figure 3G,H,
red traces). Treatment with 4a did not acutely affect
exocytosis. This data provides further evidence of specific
inhibition of SVE by 4a. The capacitance trace increased
slightly over time after the initial capacitance jump of
exocytosis with 4a treatment. This may indicate further
accumulation of fused vesicles at the plasma membrane,
increasing the membrane capacitance in the absence of
any compensatory SVE. Overall, this data shows that
4a is a more potent CME/SVE inhibitor compared to
dynasore in diverse neuronal and non-neuronal cellular
systems.
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Figure 2: Dyngo compounds are potent, reversible inhibitors of endocytosis in non-neuronal cells. A) The effect of three Dyngo
analogs 4a, 6a and 1a on endocytosis was compared with that of Dynasore (synthesized in-house) by examining Tfn-A594 uptake in
U2OS cells. B and C) The time required for 10μM 4a (B) and 6a (C) to inhibit non-neuronal CME. Dyngo compounds were preincubated
with cells before performing a Tfn uptake assay. D and E) Reversibility of endocytosis inhibition. The 10μM 4a (D) and 6a (E) were
incubated with cells for 30min and then removed. Tfn uptake was then quantified at the indicated times after removal of the compound
(washout time). Data are mean±SEM of at least three independent experiments.
Exocytosis is known to rundown after prolonged
stimulation, while endocytosis is blocked owing to a
SV rundown (2,37). We investigated the effects of 4a
on glutamate release from synaptosomes during long
repetitive stimulation (Figure 3J). Synaptosomes were
pretreated with 20μM 4a and Ca2+-dependent gluta-
mate release was stimulated by 3mM 4-aminopyridine
(4-AP), which causes repetitive action potential like stim-
ulation (38). Dyngo compound 4a-treated synaptosomes
demonstrated a decrease in the release of glutamate
only after 45 seconds of 4-AP stimulation. As Dyngo
compound 4a does not inhibit exocytosis directly (Figure
3F), this suggests that inhibition of SV recycling produces
an activity-dependent rundown in synaptic transmission.
Dyngo compound 4a inhibits both modes of SVE
There are two distinct modes of SVE in neurons: neuronal
CME and activity-dependent bulk endocytosis (ADBE)
(39,40). We investigated whether 4a inhibited both modes
in cultured CGNs by delivering high-intensity electrical
stimulation in the presence of horseradish peroxidase
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Figure 3: Legend on the next page.
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Table 4: Effect of albumin on CME potency of the Dyngo compounds
Compound 1h 10% FBS 5% FBS 1% FBS 1% BSA 0.1% BSA
Dynasore 22.2± 6.0 532 650 57.8 235 277
4a 6.3± 3.6 115± 7.5 102 23.7± 3.2 83± 12 44
6a 3.3± 0.6 108± 15 78± 7 16.5 281 46
Table shows IC50 values for inhibition of CME in U2OS cells after incubation of cells for 1 h in the presence or absence of FBS or BSA
and the indicated compound. Data are mean (μM) and SEM or range of two to four independent experiments (1 h, n= 3; 1% FBS, n=2;
10% FBS, n= 4).
(HRP), which facilitates labeling of endocytosed structures
with an electron-dense substrate (Figure 4A,B). Pretreat-
ment with 30μM 4a caused a significant reduction in the
number of labeled synaptic vesicles (Figure 4C), indicat-
ing that neuronal CME was inhibited in these neurons.
Unlabeled synaptic vesicles were also reduced, indicating
a lack of replenishment of pools by neuronal CME (Figure
4C). The incomplete abolition of SVE by 4a at a fixed
30μM concentration is in line with our earlier observation
that the IC50 for SVE inhibition is 26.8μM. In addition, 4a
caused a decrease in the number of HRP-labeled endo-
somes, indicative of a block in ADBE (Figure 4D). Using a
more quantitative assay the reduction in ADBE by 4a was
confirmed in experiments showing that 30μMof the com-
pound reduced the uptake of large fluorescent dextrans
(which are too large to accumulate in synaptic vesicles)
in cultured CGNs (Figure 4E, representative images are
shown in Figure S8E,F). Furthermore, a large number of
the residual HRP-labeled endosomes formed in the pres-
ence of 4a display an elongated tubular structure, rather
than a typical spherical appearance (Figure 4F,G). These
malformations indicate that even when ADBE occurs, the
formation of bulk endosomes shows some defects, as pre-
viously observed with 100μM dynasore (40) and in nerve
terminals of dynamin I knockout mice (41,42). The malfor-
mations are reminiscent of the shape of CLICs defined by
electronmicroscopy in fibroblasts, and this endocytic path-
way was previously shown to be unaffected by 4a (28).
We did not observe complete abolition of ADBE by 30μM
4a treatment (being a maximum of >80% block measured
by dextran uptake). This might be explained by the fact
that a concentration of 4a close to the IC50 was used.
Discussion
We report a library of dynasore analogs with greatly
increased potency, significantly reduced non-specific
binding characteristics, which are not cytotoxic and have
a markedly improved potency in cells. The best Dyngo
series compound, 4a, is shown to inhibit not only non-
neuronal CME but also SVE and ADBE at presynaptic
nerve terminals. Surprisingly, the Dyngo compounds
exhibit a marked preference for inhibition of dynamin
in its helical conformation, while dynasore showed little
preference. Helical dynamin is thought to be the form
of dynamin responsible for facilitating endocytosis in
cells. These compounds thus have broader utility and
greater versatility for cell biologists. We first found that
dynasore stoichiometrically binds to detergents routinely
used for in vitro GTPase assays. Simple modifications of
the substituents and substitution pattern of dynasore’s
Figure 3: Dyngo compound 4a inhibits SVE in synaptosomes and neurons. A–C) SVE was examined by quantifying uptake of
FM4-64 in synaptosomes stimulated with 40mM KCl. Dose–response curves and IC50 values are shown for 4a (A), 6a (B) and dynasore
(C). D–F) SVE in cultured CGNs. D) To further examine SVE inhibition by 4a, CGNs were loaded and unloaded with FM1-43 using the
protocol displayed. In both S1 and S2 load phases, dye was loaded into retrieving synaptic vesicles with 800 action potentials (80Hz
for 10 seconds). Unloading was stimulated by two sequential 30-second stimuli using 50mM KCl. The extent of SV turnover was
estimated from the total amount of dye unloading at S1 (S1) and S2 (S2). Where indicated, cultures were preincubated with 30μM
4a for 15min prior to and during either S2 loading (Endo) or unloading (Exo). E) Cumulative histograms display the ratio of S2 to S1
across a population of single synapses. Black circles show untreated control data (Ctrl). Dyngo compound 4a was either applied during
the loading phase, quantifying the effect of 4a on SVE (open circles), or during the unloading phase, which quantifies the effect on
exocytosis (gray circles). F) The mean S2/S1 response (±SEM) is displayed for control cultures (black bar, n=270 nerve terminals)
and for cultures where 4a was present in either the S2 unload (gray bar, n= 163, exocytosis) or S2 load (open bar, n= 270, endocytosis).
Dyngo compound 4a had no significant effect on exocytosis, but significantly inhibited endocytosis, one-way ANOVA, **p<0.01,
***p<0.001. G and H) The effect of 4a on whole-cell membrane capacitance was investigated at the Calyx of Held with 0.3mM 4a in
the puffing pipette. G) A sample trace shows membrane capacitance on control (black) and 4a-treated samples (red). H) Collated data
of normalized capacitance measurement from control and 4a-treated neurons (n=6). Dyngo compound 4a-treated samples showed no
inhibition in exocytosis but a dramatic reduction in endocytosis. I) Rate of membrane retrieval (paired t-test, p=0.048). All data except
(E) and (G) are means±SEM. J) Ca2+-dependent exocytosis from synaptosomes was measured after 30-min incubation in 1% DMSO
(control) or 20μM 4a. To examine whether an activity-dependent decrease in glutamate release was apparent with 4a treatment, the
average control values were subtracted from each data point, thus representing the control sample as a relative change in glutamate
release of zero. Dyngo compound 4a had no effect for the first 45–50 seconds, and subsequently caused a reduction in stimulated
exocytosis that increased with stimulation time, suggesting activity-dependent depletion in the pool of releasable synaptic vesicles in
synaptosomes. Data are mean from two experiments± range.
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catechol moiety produced a range of improved dynamin
GTPase inhibitors, with 4a and 6a showing the optimum
properties. Dyngo compounds 4a and 6a exhibit little to no
(respectively) residual detergent binding. Unlike dynasore,
4a and 6a exhibit greater potency for inhibiting PS-
stimulated helical dynamin compared to grb2-stimulated
ring dynamin, demonstrating a preference for inhibition of
the helical conformation,which has been directly observed
at the neck of vesicles undergoing endocytosis in cells.
Using the same assay conditions, 4a is 37 times more
potent than dynasore against dynamin I and is 6 times
more potent in blocking dynamin-dependent endocytosis,
while not affecting dynamin-independent endocytosis.
Dyngo series 6a shows intermediate in vitro potency,
yet is equally potent to 4a in non-neuronal cells. Dyngo
compound 6a has the advantage of retaining no detectable
non-specific detergent interaction. We propose that 4a
and 6a are improved, versatile, cell-permeable dynamin I
and II inhibitors. These findings demonstrate that simple
substitutions within the dynasore pharmacophore have
had profound effects on the specificity and cellular activity
of the compound and highlight a small compound group
with reduced non-specific interactions.
In high-throughput screening for enzyme modulators,
detergents are routinely included in enzymatic assays
because many small molecules will cause proteins to
precipitate, leading to a very high rate (up to 95%) of
false-positive hits when a compound library is screened
(43–45). Inclusion of detergent prevents small-molecule-
induced aggregation of the target enzyme. However,
dynasore was discovered by screening a library of 16 320
small molecules for inhibition of grb2-stimulated dynamin
activity (3). This screen was performed in the absence
of any detergents, such as Tween-80, which we use
in our dynamin assay, or Triton X-100 (which potently
inhibits dynamin GTPase activity and cannot normally
be used in dynamin assays in vitro). Had detergent
been included, as is routine practice in recent years,
dynasore would not likely have been discovered, owing
to its unusual detergent-binding properties, which render
it essentially inactive. We also found that dynamin itself
was rendered inactive by the inclusion of Triton X-100, but
not Tween, at very low concentrations down to 0.01%.
These observations highlight the critical importance of the
conditions used for any high-throughput assay, in that
the chosen conditions may act as a limiting factor in the
type of molecules that will be detected as hits. Therefore,
while conservative approaches, such as using detergent,
are generally recommended, it should not be assumed
that a high-throughput assay is capable of detecting all
important leads within a compound library.
Dyngo compounds 4a and 6a have a distinct activity profile
from dynasore in their ability to distinguish between the
activities of helical versus ring dynamin in vitro. Dynamin
has at least two distinct oligomerization states: (i) rings,
which form in the presence of proteins with SH3 domains
or with F-actin and is a widespread property within the
larger dynamin superfamily, and (ii) helices, which form in
the presence of lipid or microtubule templates and require
the PH domain (which is not part of the sequence of non-
classical dynamins). It is not yet known which regions of
dynamin are responsible for helical assembly, as opposed
to single ring assembly, but is likely to involve the
middle domain and/or bundle signaling element (46–50).
Dynasore was initially discovered through a screen for
compounds that inhibit grb-stimulated ring dynamin and
does not appear to discriminate ring or helix dynamin.
The mechanism of dynamin inhibition by dynasore is not
known, but the compound was reported not to affect GTP
binding, dynamin self-assembly, oligomerization or lipid
binding. The authors suggested that it targets the GTPase
domain (3). We have largely confirmed these studies for
dynasore, but found that the dynamin inhibitory action of
the family of Dyngo compounds is strongly dependent on
the specific oligomerization state of dynamin. Compound
4a was without effect on SAI activity stimulated by
removing salt and was over 100-fold weaker on grb2-
stimulated activity, both of which are mediated by ring
formation. In contrast, it was about equally potent against
dynamin stimulated by PS liposomes and microtubules,
both of which facilitate helical assembly of dynamin. Thus,
the mechanism of dynamin inhibition by 4a/6a appears
to be distinct from dynasore and involves preferential
interference with the function of a helix versus dynamin
oligomerization to the single ring state. This mechanism
of action is novel for an enzyme inhibitor. A specific
biological function for dynamin rings distinct from that
of the helix has not yet been reported. However, the
reduced activity of Dyngo compounds on dynamin rings,
while retaining potent anti-CME activity, indicates that
ring function is not directly associated with any of the
modes of CME investigated in our study. Dynamin rings
are known to be induced by short F-actin assemblies
(51), raising the possibility of a role for dynamin ring
oligomerization in actin dynamics.
Our discovery of improved dynamin inhibitors, with
narrower activity profiles and that also block endocytosis,
significantly adds to the growing palette of reported
dynamin modulators developed by our group (MiTMAB,
RTIL, Dynole, Iminodyn, Pthaladyn, Rhodadyn, Pyrimidyn
and Dyngo compounds) and provides two new discovery
tools for biomedical researchers. These dynamin inhibitors
include compounds with distinct mechanisms of action
at the PH (pleckstrin homology) domain (MiTMAB and
RTILs), allosteric sites on the G domain (Dynole and Dyngo
compounds), GTP binding (Pthaladyn compounds) or that
have dual action at both GTP and lipid binding (Pyrimidyn
compounds). We suggest that themost appropriate use of
small-molecule inhibitors in cell-based studies is to employ
more than one structurally distinct inhibitor (52), and this
stringency can be increased by also using inhibitors that
target different dynamin domains. This strategy increases
the probability of revealing a dynamin-dependent cellular
process and reduces the possibility of unexpected off-
target drug actions. The use of dynamin inhibitors with
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Figure 4: Dyngo compound 4a inhibits both CME and ADBE. Uptake of HRP in response to electrical stimulation (80Hz for
10 seconds) was examined in CGNs. Neurons were preincubated with or without 30μM 4a for 15min before and during stimulation.
Panels show typical electron micrographs of CGNs after HRP labeling and fixation, either in the absence (A) or presence of 4a (B).
HRP-labeled endosomes are indicated by arrows. Scale bar represents 100 nm. Panel (C) shows quantitation of the number of synaptic
vesicles observed in control and 4a-treated samples. Synaptic vesicles were either unlabeled (white bar) or HRP labeled (black bar).
4a treatment significantly reduced the number of unlabeled and labeled synaptic vesicles, demonstrating an inhibition of CME. Panel
(D) shows quantification of labeled and unlabeled endosomes. 4a inhibited the number of HRP-labeled endosomes, demonstrating an
inhibition of ADBE. E) 4a (30μM) inhibited uptake of fluorescent dextran in CGNs electrically stimulated at 80Hz, further suggesting
inhibition of ADBE. F and G) In electron micrographs, 4a treatment also increased the appearance of deformed HRP-labeled endosomes,
such as that shown in (F). Scale bar represents 50 nm. Quantification of the number of deformed endosomes for each condition is
shown in (G), presented as % of total endosome number. All data are means±SEM, ***p< 0.001, Student’s t-test.
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different mechanisms of action in combination with each
other provides investigators with a powerful toolkit for
more accurate molecular dissection of the role of dynamin
in multiple endocytic pathways and cytokinesis (1,16).
For example, the combined use of 4a or 6a with Dynole
compound 34-2 should be more valuable in teasing apart
the molecular steps of endocytosis, owing to their very
distinct mechanisms of actions within the same clathrin-
mediated endocytic pathway.
Materials and Methods
Materials
PS, phenylmethylsulfonylfluoride (PMSF) and Tween-80 were from
Sigma-Aldrich. GTP was from Roche Applied Science and leupeptin was
from Bachem. Gel electrophoresis reagents, equipment and protein
molecular weight markers were from Bio-Rad. Collagenase was obtained
from Roche. Paraformaldehyde (PFA) was from Merck Pty Ltd. Coverslips
were from Lomb Scientific. Penicillin/streptomycin, phosphate-buffered
salts, fetal bovine serum (FBS), Dulbecco’s minimal essential medium
(DMEM), Alexa-594-conjugated Tfn (Tfn-A594), DAPI, FM4-64, Calcein
blue-AM and FM2-10 were from Life Technologies. All other reagents
were of analytical reagent grade or better.
Endogenous dynamin I (18mg) was purified from sheep brain as described
(10) and full-length human dynamin I or rat dynamin II (both N-terminally
His-6-tagged) was recombinantly expressed from a pIEx-6 vector in insect
cells (Sf21) using polyethyleneimine (25 kDa) as the transfection reagent
using a DNA:polyethyleneimine ratio of 1:5 for 48 h and purified by affinity
purification on GST-Amph2-SH3-sepharose (21). Recombinant dynamin I
was used only for the data in Table 2. The dynamin antibodies were from:
Dynamin I – in-house YF2 antibodies, raised in rabbits against two different
synthetic peptides: dynamin I 629-647 (RVGDKEKASETEENGSDSF) and
dynamin I 765–778 (VQSVPAGRRSPTSS), used at 1/2000 dilution, as
previously described (53); Dynamin II – Santa Cruz (C-18, sc-6400, used
at 1/1000) and Dynamin III – Santa Cruz (P-13, sc-69472, used at 1/500
dilution).
Animals
All animal work performed was carried out according to institutional and
national care and ethics guidelines.
Chemical synthesis
All starting materials are described in Supporting Information. 1H and 13C
spectrawere recorded on a Bruker Advance AMX300MHz spectrometer at
300.13 and 75.48MHz or a Bruker Ascend™ 400MHz spectrometer at 400
and 100MHz, respectively. Microanalyses were performed at MicroAnalyt-
ical Unit, Research School of Chemistry at The Australian National Univer-
sity, Canberra. For the synthesis of 4a (3-hydroxynaphthalene-2-carboxylic
acid (2,4,5-trihydroxybenzylidene) hydrazide), a solution of 3-hydroxy-2-
naphthoic hydrazide (0.2022 g, 0.1mmol), 2,4,5-trihydroxybenzaldehyde
(0.1540 g, 1mmol) and ethanol (25mL) were heated to reflux for 2 h.
After this time, the reaction mixture was allowed to cool and the solvent
removed in vacuo. The resulting solid was recrystallized from ethanol
[0.162 g (45%)]. Details on yield, analysis, purity and synthesis of the other
Dyngo compounds are provided in Supporting Information.
Compounds for screening
Compounds were made as stock solutions in 100% dimethyl sulfoxide
(DMSO), which were stored frozen. These were diluted in 50% v/v
DMSO/20mM Tris–HCl pH7.4 or cell media prior to a second dilution
in the aqueous assay immediately prior to use. Compounds in aqueous
solutions were not exposed to temperature above 4◦C prior to use in the
assay.
Dynamin GTPase assay
The Malachite Green colorimetric GTPase assay was as described (10).
Dynamin I activity was measured in its SAI activity state or was stimulated
by three differentmethods. As each stimulus activates dynamin to different
extents, each assay required different dynamin concentrations. First,
maximal dynamin activity was stimulated by sonicated PS liposomes
(10). Purified dynamin I (10–20 nM, diluted in: 6mM Tris–HCl, 20mM
NaCl and 0.01% Tween 80, pH7.4) was incubated in 96-well plates
in GTPase buffer (5mM Tris–HCl, 10mM NaCl, 2mMMg2+, 0.05%
Tween 80, pH7.4, 1μg/mL leupeptin and 0.1mM PMSF) and GTP
0.3mM in the presence of test compound for 30min at 37◦C in a
final assay volume of 150μL. Reactions were terminated with 10μL
of 0.5M ethylenediaminetetraacetic acid (EDTA) pH7.4 and Malachite
Green solution (40μL: 2% w/v ammonium molybdate tetrahydrate, 0.15%
w/v malachite green and 4M HCl) was added for 5min. Second, dynamin
(20 nM) was stimulated by 10 μg/mL of taxol-stabilized preformed bovine
brain microtubules (Cytoskeleton, Inc) using the same protocol. Third,
dynamin I (50 nM) was stimulated by 1μM of recombinant growth
factor receptor-bound protein 2 (grb2), a SH3 (Src homology)-containing
protein that stimulates dynamin about 5–10 times less efficiently than
liposomes or microtubules (54). The assay conditions were as described
above. Finally, dynamin (500 nM) SAI activity was measured using high
concentrations of dynamin, which promote its cooperative self-assembly
into rings (but not helices) (26,55). The final DMSO concentration in the
GTPase or endocytosis assays was at most 3.3 or 1%, respectively, but
typically was at 1%. The GTPase assay for dynamin I was unaffected
by DMSO up to 3.3%. Compounds were dissolved as 30mM stocks in
100% DMSO. These stock solutions can be stored at −20◦C for several
months. Compounds were subsequently diluted into solutions of 50%
DMSO made up in 20mM Tris–HCl pH7.4 and diluted again into the final
assay. For analysis of the kinetics of 4a inhibition, dynamin I at a final
concentration of 17 nM was incubated with GTPase buffer containing PS
(2μg/mL) and varying amounts of GTP (50–250μM) in the presence of
4a at a concentration range between 0.5 and 6μM. The reaction was
stopped after 30min by addition of EDTA (0.5mM, pH7.4). Curves were
generated using the Michaelis–Menten equation v =Vmax[S]/(Km + [S]),
where S is the GTP substrate. After the Vmax and Km values were
determined, the data were transformed using the Lineweaver–Burke
equation, 1/v =1/Vmax + (Km/Vmax)(1/[S]).
Dynamin II GTPase assay
Assay conditions were based on the dynamin I assay but contained
modifications. Recombinant dynamin II was used at 50 nM, stimulated by
10μg/mL PS. The GTPase reaction was allowed to occur for 90min at
37◦C before termination.
Plasma protein binding
Plasma protein binding was estimated using an immobilized human serum
albumin column (ChromTech Chiral-HSA, 50×3.0mm, 5μm) with gradient
elution based on a previously published method (56).
Cell-based endocytosis
Quantitative analysis of the inhibition of Alexa 594-Tfn endocytosis in
U2OS cells was performed on large numbers of serum-starved cells
as described (10). Synaptic vesicle recycling in cultured CGNs was
monitored using FM1-43 as described (57) (see Supporting Information).
Dynamin-independent endocytosis was measured using internalization of
CT in NIH3T3 cells (using Tfn as a control) as described previously (58)
with minor changes (see Supporting Information). The average number of
cells for each data point was ∼1200. IC50 values were calculated using
GraphPad Prism 5 and data were expressed as mean±95% confidence
interval (CI) for three wells and ∼1200 cells.
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Endocytosis in synaptosomes
Highly purified synaptosomes, prepared from the cerebrum of adult
male Sprague-Dawley rats, were used to measure SVE and ADBE (59).
Synaptosomes were allowed to attach to 96-well glass-bottom plates
and endocytosis of FM4-64 was measured after 2-min KCl depolarization
(described previously) (35). Fluorescent images of synaptosomes were
acquired using an ImageXpress Micro system with a 20× air objective
at excitation 476–524 nm and emission at 608–742 nm. Images were
analyzed using MetaXpress software and fluorescence intensity values
were normalized to control uptake of dye (set at 1.0).
Primary neuronal cultures
Granule neuron cultures were prepared from the cerebella of 7-day-old rat
pups as previously described (57). In all experiments, neurons were used
between 8 and 10 days in vitro.
Glutamate release from synaptosomes
Release of glutamate from synaptosomes was performed as described
previously (60,61), with minor changes. The assay was carried out at
37◦C in a Perkin Elmer LS50 fluorimeter. Control (1% DMSO) and 4a-
treated samples were incubated in the presence of the compound for
30min prior to stimulation of glutamate release. For each sample, 1mg
of crude P2 synaptosomes was diluted in 2mL of HEPES-buffered Krebs-
like buffer, either containing 1mM EGTA (zero Ca2+) or 1mM EGTA
plus 3mM Ca2Cl (2mM free Ca2+). NAPD+ (3mM) and glutamic acid
dehydrogenase (50U) were added and allowed to incubate for 15min to
allow residual glutamate in the sample to bemetabolized. 4-AP (3mM) was
subsequently added to stimulate glutamate release, which was recorded
over a 5-min period. Readings of fluorescence were taken every 2 seconds.
All treatment conditions were carried out in zero Ca2+ and 2mM Ca2+
conditions with the zero Ca2+ measurement subtracted from the 2mM
measurement for each time point. At each time point, the average control
value was then subtracted to demonstrate activity-dependent rundown of
glutamate release. Each treatment was carried out in duplicate within a
single experiment and each independent experiment was carried out three
times on separate days using synaptosomes prepared from fresh rat brain
tissue (n=2 independent experiments).
Fluorescence imaging of SV turnover using FM1-43
Neuronal cultures were removed from culture medium and left for 10min
in incubation medium [170mM NaCl, 3.5mM KCl, 0.4mM KH2PO4,
20mM TES (N-tris[hydroxy-methyl]-methyl-2-aminoethane-sulfonic acid),
5mM NaHCO3, 5mM glucose, 1.2mM Na2SO4, 1.2mM MgCl2 and
1.3mM CaCl2, pH7.4]. Cultures were then mounted in a Warner imaging
chamber (RC-21BRFS). Invaginating membrane was loaded with FM1-43
(10μM) by evoking SV turnover with a brief train of action potentials
(80Hz for 10 seconds, 100mA and 1-millisecond pulse width, delivered
using platinum wires embedded in the imaging chamber). Dye kept
present for 1min after stimulation to ensure all retrieving membrane
was labeled (S1 loading). After a 10-min rest period, accumulated dye
was unloaded from nerve terminals using two consecutive maximal
stimuli with incubation media supplemented with 50mM KCl (50mM NaCl
removed to maintain osmolarity). The fluorescence decrease due to dye
loss provides an estimate of the total number of synaptic vesicles turned
over during stimulation (S1). After a 20-min rest period the S1 protocol
was repeated (S2 loading and unloading). Thus, for any selected nerve
terminal, the S2 response has a matched individual internal control (S1).
Dyngo compound 4a (30μM) was present for 15min prior to and including
either, S2 loading (to monitor effects on endocytosis) or S2 unloading
(exocytosis). Results are represented as either cumulative histograms
(S2/S1) for individual nerve terminals or averaged data (average S2/S1).
Dye unloading was visualized using a Nikon Diaphot-TMD epifluorescence
microscope and 20× air objective at 480-nm excitation and >510-nm
emission. Images were visualized using a Hamamatsu Orca-ER CCD
digital camera and offline imaging software (Simple PCI, Compix Imaging
Systems). At least 70 nerve terminals were selected for each experiment
and at least three independent experiments for each experimental
condition.
Fluorescence imaging of dextran uptake
Uptake of tetramethyrhodamine-dextran (40 kDa) into nerve terminals of
CGNs was monitored as described previously (40). Briefly, cells were
left for 10min in incubation medium and then stimulated with a train
of 800 action potentials (80Hz for 10 seconds) in the presence of
tetramethyrhodamine-dextran (50μM). Dyngo compound 4a (30μM) was
present for 15min prior to and including action potential stimulation.
Dextran loading was determined by the number of fluorescent puncta
in a defined field of view (130×130nm) using a 20× air objective
at 550-nm excitation and >575-nm emission. Threshold analysis was
performed to discount regions too large to represent individual nerve
terminals (diameter greater than 2 nm). The number of dextran puncta
per field for each experiment (usually 10 fields of view per experiment)
was averaged and subtracted from background fluorescence. To ensure
that the density of nerve terminals was consistent between fields and
experimental conditions, experiments were performed on the same set of
cultures.
Labeling of endocytosis pathways by horseradish
peroxidase
Granule neurons were processed for electron microscopy as previously
described (40). Briefly, cells were transferred to incubation medium
for 10min and subsequently incubated with or without 30μM 4a for
15min. Cultures were next stimulated with 800 action potentials (80Hz) in
incubation medium supplemented with HRP (10mg/mL) in the presence
or absence of 4a. Cells were fixed in a 2% solution of glutaraldehyde
in phosphate-buffered saline for 30min at 37◦C directly after stimulation.
After washing with 100mM Tris (pH7.4) cells were exposed to 0.1%
diaminobenzidine and 0.2% H2O2 in 100mM Tris. On development of
color, cells were washed with 100mM Tris and subsequently stained
with 1% osmium tetroxide for 30min. After washing, cells were post-
stained with 2% uranyl acetate for 15min, then dehydrated using ethanol
series and polypropylene oxide and embedded using Durcupan. Samples
were sectioned, mounted on grids and viewed using a FEI Tecnai 12
transmission electron microscope. Intracellular structures that were less
than 100nm in diameter were arbitrarily designated to be synaptic vesicles,
whereas larger structures were designated to be endosomes.
Capacitance measurements of endocytosis at the
Calyx of Held
Capacitance measurements at the Calyx of Held methods were previously
described (62,63). C57/SV129 mixed background mice (7–10 days old)
were decapitated. Transverse slices of 200-μm thick were cut from the
auditory brainstem with a vibratome. Recordings were made at room
temperature in a solution that pharmacologically isolated Ca2+ currents.
This solution contained (in mM) 105 NaCl, 20 TEA-Cl, 2.5 KCl, 1 MgCl2,
2 CaCl2, 25 NaHCO3, 1.25 NaH2PO4, 25 dextrose, 0.4 ascorbic acid,
3 myo-inositol, 2 sodium pyruvate and 0.001 tetrodotoxin (TTX), pH7.4,
when bubbled with 95% O2/5% CO2. The presynaptic pipette (3–5 M)
solution contained (in mM) 125 Cs-gluconate, 20 CsCl, 4Mg-ATP, 10
Na2-phosphocreatine, 0.3 GTP, 10 HEPES and 0.05 BAPTA, pH adjusted
to 7.2 with CsOH. Presynaptic whole-cell recordings were made with
an EPC-9 amplifier (HEKA Electronics). The series resistance (<20 M)
was compensated by 60%. Holding potential was −80mV. Currents were
low-pass filtered at 5 kHz and digitized at 20 kHz.
The membrane capacitance was measured with the EPC-9 amplifier
together with the software lock-in amplifier (PULSE, HEKA Electronics)
before and after 20-millisecond depolarization to assay the corresponding
exocytosis and endocytosis. A sinusoidal stimulus was applied in addition
to the DC holding potential (−80mV). The peak-to-peak voltage of the
sine wave was 10mV to avoid activation of the Ca2+ currents. The
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resulting current was processed via the Lindau–Neher technique (44) to
give estimates of the membrane capacitance, membrane conductance
and the series conductance. The sine wave frequency was 1000Hz. The
reversal potential of the measured DC current was assumed to be 0mV
(44). During step depolarization the capacitance was not measured. The
capacitance jump was measured as the difference between the averaged
capacitance value in 0.4 seconds after stimulation and the baseline value.
The capacitance jump returned to the baseline in a few seconds to tens
of seconds. The interval between two voltage commands was at least
2min to complete readily releasable pool replenishment and avoid short-
term synaptic plasticity induced by the previous voltage command. All
capacitance traces shown in the figures were taken from single recordings
and were low-pass filtered at 200Hz. Dyngo compound 4a or dynasore
was applied extracellularly via local puffing. We positioned glass pipettes
(1.5–2.5 M) containing 0.3mM 4a or 0.8mM dynasore plus the bath
solution described below close (<5 μm) to the surface of postsynaptic
cells. The 4a or dynasore solutions were pressure injected (4 psi) onto the
surface of the synapse with a pneumatic picopump (Picospitzer III, Parker
Hannifin Co).
Dynamin-independent CT endocytosis
Internalization of CT and Tfn in NIH3T3 cells was performed as described
previously (58) with minor changes. Uptake of 5 μg/mL Tfn-488 (Invitrogen)
and 2 μg/mL CT-555 (Invitrogen) was carried out constitutively at 37◦C in
serum-free DMEM (Gibco) for 5min. Cells were washed 2×1min with
glycine pH2.2 to remove any cell surface labeling of CT (64). Cells were
fixed in 4% PFA and imaged with a 510 Meta Zeiss confocal microscope.
Calculation of CT-555 and Tfn-488 fluorescence intensity was as described
(58). In brief, images were processed in Adobe Photoshop CS2. All images
were captured under the same detection settings and a threshold was
applied. The mean pixel intensity and number of pixels obtained from
the histogram were used to calculate total fluorescence intensity per cell.
Control cells were normalized to 100% and each sample was recalculated
in relation to control cells to give fluorescence intensity as a percentage of
control cells.
All other methods are described in Supporting Information.
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Table S1. MTT analysis of different human cancer cell lines after 72 h of
incubation with Dyngo analogs. GI50 (μM) is the concentration that inhibits
cell growth by 50% (the lower the value the greater the growth inhibition).
Errors represent SEM (n=3 independent experiments).
Appendix S1. Dyngo library 2.
Scheme S1. Scheme for the synthesis of Dyngo analogs.
Figure S1. Dynasore is a poor dynamin I inhibitor when assayed in
the presence of Tween-80. A) Structure of dynasore. B) Dose-dependent
inhibition by dynasore of dynamin I GTPase activity stimulated by PS
liposomes in the presence of Tween-80. C) IC50 values of dynamin I after
activation by four mechanisms in the presence of Tween-80. Dynasore
was either produced in house (synthesized), purchased from Sigma or
obtained from the laboratory of Tom Kirchhausen (TK). Dynasore was
tested at a range of concentrations up to a maximum of 1mM, with the
exception of data marked with *, which were tested up to 1.5mM. D)
Effect of dynasore on endocytosis of Tfn-A594 in U2OS cells. All data are
means±SEM of three independent experiments.
Figure S2. Dyngo compound 4a has no effect on dynamin binding
to SH3 domains. Pull down of dynamin I in the absence or presence of
the indicated 4a concentrations was performed using the SH3 domains of
Grb2, endophilin I or amphiphysin I attached to GSH beads. The proteins
were resolved on 12% SDS-PAGE gels and visualized using Coomasie
Blue. The results are shown for one experiment performed in triplicate and
the same results were obtained in two further independent experiments
(in duplicate).
Figure S3. Dyngo compounds do not affect amphiphysin
protein–protein interactions. The effect of dynasore and Dyngo
compounds on binding of clathrin heavy-chain C-terminal domain or AP-2
alpha ear domain to amphiphysin 1 PRD+CLAP domains determined by
ELISA assays. Data are mean and error bars represent SEM for triplicate
measurements for n=1.
Figure S4. Dyngo series 4a, 6a and dynasore are non-toxic and do
not affect cell viability in HeLa cells. A and B) HeLa cells were exposed
to MiTMAB or the indicated Dyngo compound for 8 h in the presence (A)
and absence of serum (B) and then analyzed using an LDH assay. Data
represent SEM (n=2 independent experiments). C–F) Cell membrane
integrity as an indicator of viability (C and E) and cell proliferation (D and F)
in HeLa cells were analyzed after prolonged exposure (20 h) to 4a, 6a and
dynasore in the presence (C and D) and absence of serum (E and F) using
a trypan blue exclusion assay. Data represent SEM (n=2 independent
experiments).
Figure S5. Effect of dynasore analogs on mitochondria in HeLa cells.
A) HeLa cells stably expressing H2B-mCherry (red) were serum-starved,
incubated with Mitotracker Green FM (green) and imaged by confocal
microscopy. The left panel shows cells at 40×magnification, while the right
panel shows greater detail of mitochondrial structure. All nuclei exhibited
red fluorescence, although the intensity varied considerably. Cells were
then treated with either DMSO (B), 30μM 4a (C), 100μM dynasore
(D) or 30μM 6a. In (B) to (E), left-hand panels show images acquired
30min after treatment, central panels show a more detailed image of
mitochondria after 30min of treatment and the right-hand panels show
the cells after 60min. After 30min of treatment, 4a- and dynasore-treated
cells exhibited unchanged mitochondrial morphology, including elongated
mitochondria (arrows in A–D), while 6a-treated cells exhibited relatively
fragmented mitochondria (arrows in E). After 60min of treatment, all
treated cells exhibited a reduction in Mitotracker Green FM fluorescence.
Scale bars=20μm for images in left- and right-hand panels, while for
zoomed panels the scale bar= 5μm.
Figure S6. U2OS cells express only dynamin II. Equal protein load
(50μg) from four different cancer cell lines was run on SDS gels along with
0.2μg partially purified full-length recombinant dynamin I, II or III. The three
dynamins were detected with isoform-specific antibodies by western blot.
Results shown are for one experiment with duplicate or triplicate cell
samples and similar results were obtained in two additional experiments.
Figure S7. Dyngo compound 4a does not block dynamin-independent
endocytosis of cholera toxin. A) NIH3T3 cells were serum starved for 3 h
in unsupplemented DMEM. Cells were subsequently pretreated (or not)
for 20min with 20, 50 or 80 μM 4a or dynasore. Cells were next incubated
with 5 μg/mL Tfn-488 and 2 μg/mL CT-555 in the continued presence of
20, 50 or 80 μM 4a or dynasore for 5min at 37◦C. 2×1-min washes with
0.5M glycine and pH2.2 were performed to remove surface labeling of
Traffic 2013; 14: 1272–1289 1287
McCluskey et al.
CT-555 prior to fixation in 4% paraformaldehyde. Cells were imaged on
a 510 Meta Zeiss confocal microscope. Scale bar is 10μm. B) Over 50
cells treated with each condition in (A) were imaged and fluorescence
intensity was calculated based on each unique histogram profile. Each
treated sample was calculated as a percentage of control units. All data
are means±SEM.
Figure S8. Blockade of synaptic vesicle turnover in CGNs.A–D) Activity-
dependent loading and unloading of the styryl dye FM1-43 in CGN cultures.
Representative images either loaded at S1 (A) or S2 (B) in the absence
of 4a or in its presence (S1 – panel C; S2 – panel D) are displayed.
Scale bar represents 1 μm. E and F) Dextran endocytosis specifically
reflects ADBE relative to CME. Representative images of control (E) or 4a
(panel F, 30μM, 15-min preincubation) inhibition of uptake of fluorescent
tetramethyrhodamine-dextran (50μM) in CGNs electrically stimulated by
a train of 800 action potentials (80Hz) followed by immediate dextran
washout.
Figure S9. Dynasore inhibits SVE in neurons. The effect of dynasore on
whole-cell membrane capacitance was investigated at the Calyx of Held
in parallel with the experiments in Figure 4 except that there was 0.8mM
dynasore in the puffing pipette. A) A sample trace shows membrane
capacitance on control (black) and dynasore-treated samples (red). B)
Collated data of normalized capacitance measurement from control and
dynasore-treated neurons (n= 7).
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